In This Article:
As the U.S. stock market navigates mixed performances and anticipates key economic data, investors are keeping a close eye on various sectors for potential opportunities. Penny stocks, though often seen as relics of past market eras, continue to offer intriguing possibilities by highlighting smaller or newer companies that may provide both affordability and growth potential. By focusing on those with strong financial health, investors can uncover opportunities that align with their investment goals amidst the current market dynamics.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Financial Health Rating |
| BAB (OTCPK:BABB) | $0.81 | $5.79M | ★★★★★★ |
| Inter & Co (NasdaqGS:INTR) | $4.25 | $1.93B | ★★★★☆☆ |
| QuantaSing Group (NasdaqGM:QSG) | $3.08 | $100.69M | ★★★★★★ |
| Kiora Pharmaceuticals (NasdaqCM:KPRX) | $3.7257 | $11.81M | ★★★★★★ |
| ZTEST Electronics (OTCPK:ZTST.F) | $0.32 | $11.77M | ★★★★★★ |
| Permianville Royalty Trust (NYSE:PVL) | $1.41 | $46.86M | ★★★★★★ |
| BTCS (NasdaqCM:BTCS) | $2.49 | $44.59M | ★★★★★★ |
| Smith Micro Software (NasdaqCM:SMSI) | $1.37 | $28.91M | ★★★★★☆ |
| CBAK Energy Technology (NasdaqCM:CBAT) | $0.97 | $91.74M | ★★★★★☆ |
| Safe Bulkers (NYSE:SB) | $3.45 | $365.18M | ★★★★☆☆ |
Click here to see the full list of 726 stocks from our US Penny Stocks screener.
Here's a peek at a few of the choices from the screener.
Marqeta
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Marqeta, Inc. operates a cloud-based open application programming interface platform providing card issuing and transaction processing services, with a market cap of approximately $1.94 billion.
Operations: The company generates revenue primarily from services to financial companies, amounting to $490.03 million.
Market Cap: $1.94B
Marqeta, Inc. has recently become profitable, reporting a net income of US$54.41 million for the first nine months of 2024, compared to a significant loss in the previous year. Despite this turnaround, its return on equity remains low at 1.3%, and earnings are expected to decline by an average of 21.6% annually over the next three years. The company is debt-free and has strong short-term asset coverage over its liabilities but faces legal challenges due to alleged misleading statements during a specified period in 2024. Recent partnerships and product launches aim to enhance its BNPL offerings amidst these challenges.
-
Navigate through the intricacies of Marqeta with our comprehensive balance sheet health report here.
Nautilus Biotechnology
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Nautilus Biotechnology, Inc. is a development stage life sciences company focused on creating a platform technology to quantify and unlock the complexity of the proteome, with a market cap of $215.97 million.